|transkript 1/2025 is here!
|transkript, one of our German magazines, has been the leading industry publication for biotechnology and life sciences in German-speaking Europe since 1995. It covers current information, opinions, and background on business, research, and politics.
In this issue:
Oncology is the focus of biotechnology companies in drug development in Germany, Austria and Switzerland. The pipeline includes a large number of early projects, but what happens later, on the threshold of the patient? An attempt at an overview.
The second major topic deals with the federal elections: Just in time for the election, the innovation agency SPRIND and bioeconomy experts are calling for investment in the development of a high-tech bioeconomy to lead Germany out of recession in light of the billions invested by other economies. What the parties are planning in the new legislature in terms of biotech production, new genomic technologies, synbio, etc.
Topics:
- Approval for InflaRx NV
- 300 days in Martinsried – Interview with Christian Gnam from the Innovation and Start-up Centre
- IPO of BioVersys AG
- Transcript in person: Prof Dr Niels Riedemann, InflaRx NV
- Green Deal under pressure and a break for climate protection?
- EU Commission presents EU Biohub and Competition Compass
- GFFA: Sixty-two agriculture ministers vote in favour of sustainable expansion of the low-tech bioeconomy
- Enzyme structure analysis brings fertiliser from the atmosphere one step closer
- RNA assay identifies antibiotic-resistant pathogens better than DNA-based PCR gold standard
- Artificial intelligence: help for radiologists
|transcript Special CDMO
Laborwelt-Spezial Laborautomation – News from SLAS 2025
Click here for the magazine.